Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
18,258
Total Claims
$4.0M
Drug Cost
1,107
Beneficiaries
$3,627
Cost/Patient
Risk Score Breakdown 36/100
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
-8%
Cost per patient vs peers
$3,627 vs $3,933 avg
-60%
Brand preference vs peers
20.7% vs 51.2% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
2.4%
Opioid Rate
436
Opioid Claims
$9,091
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 3,671 claims · $3.7M
Generic: 14,048 claims · $282K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 267 | $487K |
| Semaglutide | 193 | $353K |
| Dapagliflozin Propanediol | 234 | $271K |
| Apixaban | 222 | $215K |
| Insulin Aspart Prot/Insuln Asp | 86 | $208K |
| Insulin Glargine,hum.Rec.Anlog | 192 | $171K |
| Insulin Lispro | 108 | $167K |
| Empagliflozin | 118 | $159K |
| Insulin Lispro | 93 | $131K |
| Insulin Aspart | 75 | $129K |
| Insulin Regular, Human | 44 | $113K |
| Tirzepatide | 54 | $112K |
| Sitagliptin Phosphate | 76 | $94K |
| Insulin Glargine,hum.Rec.Anlog | 46 | $82K |
| Insulin Lispro Protamin/Lispro | 29 | $72K |
Prescribing Profile
Patient Profile
74
Avg Age
54%
Female
1.25
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About